Related Experiment Video

Updated: Nov 9, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Antiplatelet and anticoagulation strategies for left ventricular assist devices

Renzo Y Loyaga-Rendon1, Toshinobu Kazui2, Deepak Acharya3

  • 1Spectrum Health, Grand Rapids, MI, USA.

Annals of Translational Medicine
|April 14, 2021
PubMed

Insights

Managing left ventricular assist devices (LVADs) requires careful antiplatelet and anticoagulation strategies to minimize bleeding and clotting complications. Optimizing these therapies is crucial for better LVAD patient outcomes.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Left ventricular assist devices (LVADs) significantly improve advanced heart failure management.
  • Hemorrhagic and thrombotic complications remain critical challenges in LVAD therapy.
  • Antiplatelet and anticoagulation strategies are central to LVAD management and outcomes.

Purpose of the Study:

  • To provide a comprehensive review of antiplatelet and anticoagulation management in LVAD patients.
  • To elucidate the interplay between LVAD complications and anticoagulant therapies.
  • To optimize outcomes through a thorough understanding of LVAD management.

Main Methods:

  • Review of historical data, epidemiology, and pathophysiology of LVAD complications.
  • Discussion of platelet and anticoagulation biology.
  • Analysis of pre-, intra-, and post-implantation considerations for anticoagulation.

Main Results:

  • Detailed examination of thrombotic and hemorrhagic complication management.
  • Specific focus on heparin-induced thrombocytopenia, anticoagulant reversal, novel oral anticoagulants, artificial heart valves, and noncardiac surgeries.
  • Emphasis on the importance of integrated patient, device, and management strategies.

Conclusions:

  • Effective antiplatelet and anticoagulation management is essential for mitigating LVAD-related complications.
  • A deep understanding of anticoagulation principles and complication management is key to improving LVAD patient survival and quality of life.
  • This review offers a state-of-the-art guide for clinicians managing LVAD patients.

Keywords:
Heart failure (HF)anticoagulationantiplateletleft ventricular assist devices (LVAD)

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
80
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
94
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
138
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
107
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
819